Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (Nasdaq: INBS) entered a private placement to raise approximately $10.0 million in gross proceeds by selling 2,298,850 common shares (or pre-funded warrants) and issuing Series K-1 and K-2 warrants exercisable to purchase up to an additional 2,298,850 shares each at a $4.10 exercise price.

The securities are being sold at a combined purchase price of $4.35 per share (or pre-funded warrant) plus associated warrants, with closing expected on or about January 2, 2026. Ladenburg Thalmann is the exclusive placement agent. Proceeds are intended for working capital and general corporate purposes. The company will file a resale registration statement within 10 calendar days and aims for effectiveness no later than 45 days after the agreement.

Intelligent Bio Solutions (Nasdaq: INBS) announced a strategic manufacturing partnership with Syrma Johari MedTech to scale production of its Intelligent Fingerprinting Drug Screening Reader ahead of planned U.S. market entry in 2026.

The collaboration is expected to deliver >40% annual production cost savings, an ~20 percentage‑point improvement in gross margin versus the prior arrangement, and ~4x current manufacturing capacity through Syrma Johari’s 14 facilities and 1.1M+ sq ft footprint. Syrma Johari holds ISO 13485, MDSAP, FDA, TUV SUD, and GMP certifications to support global regulatory needs.

Intelligent Bio Solutions (Nasdaq: INBS) announced a non-exclusive strategic alliance with Vlepis on Dec 18, 2025 to collaborate on R&D, distribution, and regulatory work for non-invasive testing and wearable patch technologies.

The partnership aims to extend INBS’ Intelligent Fingerprinting and SMARTOX SmarTest Patch into consumer health monitoring, leveraging Vlepis’ wearable sensors and cloud/mobile connectivity to accelerate international commercialization and broaden revenue opportunities.

Intelligent Bio Solutions (Nasdaq: INBS) will effect a 1‑for‑10 reverse stock split at 11:59 PM ET on December 15, 2025, with split‑adjusted trading resuming on Nasdaq at the open on December 16, 2025 under the symbol INBS and new CUSIP 36151G709.

The split was approved by stockholders on October 16, 2025; every 10 shares issued and outstanding will be combined into one share and outstanding equity awards and warrants will be proportionately adjusted. No fractional shares will be issued; holders entitled to fractions will receive a cash payment in lieu of a fractional share. Par value remains $0.01 and authorized shares remain at 100,000,000. Immediately after the reverse split, approximately 959,533 shares will be issued and outstanding.

Intelligent Bio Solutions (NASDAQ: INBS) announced management will participate in Noble Capital Markets’ 21st Annual Emerging Growth Equity Conference on December 2–3, 2025 in Boca Raton, Florida.

The company will present on Wednesday, December 3, 2025 at 11:00 a.m. ET in Presentation Room 2 at Florida Atlantic University. A webcast recording will be available the following day on the company investor relations site, Noble’s website, and Channelchek for 90 days.

Investors may register with discount code INBSNOBLECON. To schedule one-on-one meetings or request more information, contact a Noble Capital Markets representative or email KCSA Strategic Communications at INBS@ksca.com.

Intelligent Bio Solutions (Nasdaq: INBS) reported fiscal 2026 first quarter results for the period ended September 30, 2025, delivering record quarterly revenue of $1,111,797, up 32% sequentially and 28% year‑over‑year. Cartridge consumable sales totaled $640,300, representing 57.59% of revenue. Gross profit margin improved by 690 basis points to 46.6%, attributed to operational efficiency and a higher mix of cartridge sales. The company added 33 net new customer accounts (total active accounts: 492 across 24+ countries), secured a multi‑site contract in London covering 4,400 staff, launched the SmarTest Patch, and signed a global distribution agreement with SMARTOX for markets outside the U.S. and Canada.

Management highlighted consumable‑led recurring revenue momentum and margin expansion while advancing toward planned FDA clearance and U.S. market entry.

Intelligent Bio Solutions (NASDAQ: INBS) reported preliminary, unaudited fiscal Q1 2026 revenue of over $1.0 million, a record for the company, representing approximately +32% sequential and +28% year‑over‑year growth for the quarter ended September 30, 2025.

Revenue strength was driven by new customer accounts and higher product demand: cartridge revenue +43% YoY and reader revenue +23% YoY. This marks the company’s third consecutive quarter of revenue growth and reflects an increasing share of higher‑margin consumables in the sales mix.

Results are preliminary and subject to adjustment; final Q1 2026 financials will be filed on Form 10‑Q during the week commencing November 10, 2025.

Intelligent Bio Solutions (Nasdaq: INBS) announced it added 33 new customer accounts in fiscal Q1 ended Sept 30, 2025, a 50% year-over-year increase, bringing total active accounts to over 480. Growth concentrated in maritime, transportation & logistics, electrical/electronic manufacturing, construction, and newly entered government administration sectors. About 91% of new accounts were first-time adopters; 9% were expansions. Regional expansion was strongest in the UK with distributor activity across Europe and the Middle East. The company positioned its fingerprint-based non-invasive drug screening to address a projected global market of $17.1B by 2029 (CAGR 15%).

Intelligent Bio Solutions (Nasdaq: INBS) announced a major new UK commercial contract on October 23, 2025 with a multinational industrial service provider that employs ~3,000 staff in the UK and Ireland and > 30,000 worldwide. The deployment is described as one of INBS's most significant UK commercial rollouts to date and moves the customer from urine-based third-party testing to INBS's rapid, non-invasive Intelligent Fingerprinting Drug Screening System.

The customer expects faster, less disruptive testing, shorter detection windows, improved employee experience, and on-site rapid results. INBS said this supports recurring cartridge revenue and follows prior deployments across transportation, construction, and mining; INBS reports > 480 accounts in 24 countries and 18 distribution partners. The company is pursuing FDA 510(k) clearance to expand U.S. workplace use beyond Forensic Use Only.